整理 | GLP1减重宝典内容团队 最近对 STEP 计划的五项随机对照试验进行的分析发现， 使用司美格鲁肽治疗肥胖的成年人比使用安慰剂的成年人更有可能减少或停 止使用抗高血压和降脂药物 。值得注意的是，两组之间的药物调整存在显著差异，司美格鲁肽使用者的减少幅度更大。 该研究结果于 2025 年 1 月 5 日在线发表在《肥胖》上，研究人员指出，司美格鲁肽是一种胰高血糖素样肽-1 (GLP-1) 受体激动剂，广 泛用于体重管理，并与多种代谢参数的改善有关。观察到的抗高血压和降脂药物使用量的减少与体重显着减轻对血压和血脂状况的已知 影响相一致。他们建议，通过促进治疗强度降低或停药，司美格鲁肽可能为患有肥胖相关心脏代谢疾病的个体简化用药方案提供额外的 优势。 基于上述背景，Beverly G. Tchang 及其同事旨在评估接受司美格鲁肽 2.4 毫克治疗的参与者与接受安慰剂治疗的参与者相比，抗高血 压和降脂治疗的变化。他们分析了五项司美格鲁肽对肥胖人群的治疗效果 (STEP) 试验的汇总数据。 为此，研究人员评估了司美格鲁肽 2.4 毫克在 STEP 临床试验中的疗效和安全性。在这项事后分析中，STEP 1、3 ...

Group 1 - The company is planning a major asset restructuring involving the acquisition of controlling stakes in Zigong Xipu Materials Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. through share issuance and/or cash payment [4] - The valuation of Xipu Materials and Beid Pharmaceutical has not been finalized as of the announcement date, and the transaction will not result in a change of control for the company [1] - The stock of the company has been suspended from trading since September 8, with an expected disclosure of the transaction plan within 10 trading days [1] Group 2 - Xipu Materials specializes in technology services, integrated circuit chip sales, and advanced materials for the semiconductor market, aiming to become a primary supplier of electronic-grade materials [1] - Beid Pharmaceutical, a subsidiary of the company, reported a revenue of 144 million yuan and a net profit of 4.04 million yuan in the first half of the year, with total assets of 464 million yuan and net assets of 346 million yuan as of June 30 [1][2] - Beid Pharmaceutical has achieved several accolades in drug research and innovation, including being recognized as a "Provincial Specialized and Innovative Enterprise" and a "Provincial Innovative Enterprise" [2]